RINVOQ COMPLETE Trademark

Trademark Overview


On Wednesday, May 24, 2023, a trademark application was filed for RINVOQ COMPLETE with the United States Patent and Trademark Office. The USPTO has given the RINVOQ COMPLETE trademark a serial number of 98010550. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, May 21, 2024. This trademark is owned by AbbVie Biotechnology Ltd. The RINVOQ COMPLETE trademark is filed in the Education & Entertainment Services and Computer & Software Services & Scientific Services categories with the following description:

Providing a website featuring nondownloadable publications in the nature of brochures, articles and newsletters in the field of health; Educational services, namely, training in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive web sites
rinvoq complete

General Information


Serial Number98010550
Word MarkRINVOQ COMPLETE
Filing DateWednesday, May 24, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, May 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 26, 2024

Trademark Statements


Goods and ServicesProviding a website featuring nondownloadable publications in the nature of brochures, articles and newsletters in the field of health; Educational services, namely, training in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof
Goods and ServicesProviding medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive web sites

Classification Information


International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateSunday, June 25, 2023
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, June 25, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAbbVie Biotechnology Ltd
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHamilton HM11
BM

Party NameAbbVie Biotechnology Ltd
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHamilton HM11
BM

Trademark Events


Event DateEvent Description
Saturday, May 27, 2023NEW APPLICATION ENTERED
Sunday, June 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 6, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 6, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 26, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 26, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 21, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, February 16, 2024ASSIGNED TO EXAMINER
Monday, November 11, 2024TEAS STATEMENT OF USE RECEIVED